JP7161940B2 - がんの治療のための、補体不活性化に耐性のエンベロープウイルス - Google Patents

がんの治療のための、補体不活性化に耐性のエンベロープウイルス Download PDF

Info

Publication number
JP7161940B2
JP7161940B2 JP2018564966A JP2018564966A JP7161940B2 JP 7161940 B2 JP7161940 B2 JP 7161940B2 JP 2018564966 A JP2018564966 A JP 2018564966A JP 2018564966 A JP2018564966 A JP 2018564966A JP 7161940 B2 JP7161940 B2 JP 7161940B2
Authority
JP
Japan
Prior art keywords
sequence
virus
fusion protein
seq
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018564966A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020519230A5 (cg-RX-API-DMAC10.html
JP2020519230A (ja
Inventor
ティアンチ ルオ
ルネ モリーナ
ガブリエル カスティーユ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellstat ImmunoTherapeutics LLC
Original Assignee
Wellstat ImmunoTherapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat ImmunoTherapeutics LLC filed Critical Wellstat ImmunoTherapeutics LLC
Publication of JP2020519230A publication Critical patent/JP2020519230A/ja
Publication of JP2020519230A5 publication Critical patent/JP2020519230A5/ja
Application granted granted Critical
Publication of JP7161940B2 publication Critical patent/JP7161940B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18151—Methods of production or purification of viral material
    • C12N2760/18152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018564966A 2017-05-10 2018-05-10 がんの治療のための、補体不活性化に耐性のエンベロープウイルス Active JP7161940B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762504120P 2017-05-10 2017-05-10
US62/504,120 2017-05-10
PCT/US2018/032018 WO2018209052A1 (en) 2017-05-10 2018-05-10 Enveloped virus resistant to complement inactivation for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2020519230A JP2020519230A (ja) 2020-07-02
JP2020519230A5 JP2020519230A5 (cg-RX-API-DMAC10.html) 2021-05-20
JP7161940B2 true JP7161940B2 (ja) 2022-10-27

Family

ID=64105722

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018564966A Active JP7161940B2 (ja) 2017-05-10 2018-05-10 がんの治療のための、補体不活性化に耐性のエンベロープウイルス

Country Status (13)

Country Link
US (2) US11274141B2 (cg-RX-API-DMAC10.html)
EP (1) EP3621635A4 (cg-RX-API-DMAC10.html)
JP (1) JP7161940B2 (cg-RX-API-DMAC10.html)
KR (3) KR102839445B1 (cg-RX-API-DMAC10.html)
CN (3) CN121343934A (cg-RX-API-DMAC10.html)
AU (1) AU2018265258B2 (cg-RX-API-DMAC10.html)
BR (1) BR112018075281A2 (cg-RX-API-DMAC10.html)
CA (1) CA3026892A1 (cg-RX-API-DMAC10.html)
IL (1) IL263979B2 (cg-RX-API-DMAC10.html)
MX (1) MX2018015599A (cg-RX-API-DMAC10.html)
NZ (1) NZ748798A (cg-RX-API-DMAC10.html)
WO (1) WO2018209052A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201808040B (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
CN112759654A (zh) * 2019-11-06 2021-05-07 深圳普菲科生命科技有限公司 一种病毒囊膜蛋白装配系统及其方法和应用
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
EP4299729A4 (en) * 2021-02-26 2025-06-11 SillaJen, Inc. ONCOLYTIC VIRUS AND USE THEREOF
CN113736810B (zh) * 2021-09-08 2024-05-24 苏州因特药物研发有限公司 构建体、载体、蛋白、细胞、制备方法、产品及应用
KR102983542B1 (ko) * 2022-06-29 2026-06-30 신라젠(주) Cd55 및 cd59를 동시 발현하는 항암 바이러스
KR20240035360A (ko) * 2022-09-07 2024-03-15 신라젠(주) 항암 바이러스의 신규 용도

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002509695A (ja) 1997-11-21 2002-04-02 ゲセルシャフト フュア バイオテクノロギッシェフォーシュング エムベーハー（ゲーベーエフ） 一本鎖ｄｎａ又は二本鎖ｄｎａ、コード化融合タンパク質，ウイルス，パッケージング細胞及びこれらの使用ヒト補体システムによる不活化に耐えるウイルスの開発
JP2008507272A (ja) 2004-07-21 2008-03-13 ダナ−ファーバー キャンサー インスティチュート，インコーポレイテッド レンチウイルスベクターおよびその使用
JP2008061539A (ja) 2006-09-05 2008-03-21 Osaka Univ ヒト補体制御因子発現遺伝子およびその利用
WO2016174407A1 (en) 2015-04-27 2016-11-03 Ucl Business Plc Nucleic acid construct for expressing more than one chimeric antigen receptor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374548A (en) * 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
ES2310580T3 (es) 1993-04-30 2009-01-16 Wellstat Biologics Corporation Composiciones purificadas del virus de la enfermedad de newcastle.
JPH10313865A (ja) * 1997-05-15 1998-12-02 Deinabetsuku Kenkyusho:Kk ヒト補体制御因子が呈示されたベクター
IL136905A0 (en) 1997-12-22 2001-06-14 Univ Tennessee Res Corp Recombinant rhabdovirus containing a heterologous fusion protein
CA2324284A1 (en) * 1998-04-02 1999-10-14 Rigel Pharmaceuticals, Inc. Peptides causing formation of compact structures
CN1477964A (zh) 1999-04-15 2004-02-25 应用病毒治疗肿瘤
CN100594037C (zh) 2002-11-15 2010-03-17 Musc研究发展基金会 通过补体受体2定向的补体调节剂
US20100120628A1 (en) * 2007-02-06 2010-05-13 Genizon Biosciences Inc. Genemap of the human genes associated with adhd
MX2009009200A (es) 2007-03-01 2009-10-28 Advanced Vision Therapies Inc Tratamiento de enfermedades caracterizadas por la inflamacion.
US8877896B2 (en) 2008-02-15 2014-11-04 Tufts University Compositions, methods and kits for modeling, diagnosing, and treating complement disorders
JP2014516517A (ja) 2011-04-29 2014-07-17 キージーン・エン・フェー グリホサート耐性強化
SG194780A1 (en) 2011-05-05 2013-12-30 Wellstat Immunotherapeutics Llc Complement factor b analogs and their uses
BR112014013205A2 (pt) * 2011-12-01 2020-10-27 Protevobio, Inc. proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit
SG10202109752XA (en) * 2014-04-07 2021-10-28 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
EP3805371A1 (en) 2014-05-15 2021-04-14 National University of Singapore Modified natural killer cells and uses thereof
SG11201708257UA (en) 2015-04-06 2017-11-29 Subdomain Llc De novo binding domain containing polypeptides and uses thereof
AU2016274989A1 (en) 2015-06-12 2017-11-02 Immunomedics, Inc. Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
CN109415706A (zh) 2016-05-19 2019-03-01 图恩斯通有限合伙公司 假型化的溶瘤弹状病毒及其在组合治疗中的应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002509695A (ja) 1997-11-21 2002-04-02 ゲセルシャフト フュア バイオテクノロギッシェフォーシュング エムベーハー（ゲーベーエフ） 一本鎖ｄｎａ又は二本鎖ｄｎａ、コード化融合タンパク質，ウイルス，パッケージング細胞及びこれらの使用ヒト補体システムによる不活化に耐えるウイルスの開発
JP2008507272A (ja) 2004-07-21 2008-03-13 ダナ−ファーバー キャンサー インスティチュート，インコーポレイテッド レンチウイルスベクターおよびその使用
JP2008061539A (ja) 2006-09-05 2008-03-21 Osaka Univ ヒト補体制御因子発現遺伝子およびその利用
WO2016174407A1 (en) 2015-04-27 2016-11-03 Ucl Business Plc Nucleic acid construct for expressing more than one chimeric antigen receptor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Molecular therapy，2005年，11(4)，645-651

Also Published As

Publication number Publication date
NZ748798A (en) 2026-03-27
CN121343935A (zh) 2026-01-16
ZA201808040B (en) 2019-09-25
CN109414483A (zh) 2019-03-01
US11274141B2 (en) 2022-03-15
WO2018209052A1 (en) 2018-11-15
CN121343934A (zh) 2026-01-16
JP2020519230A (ja) 2020-07-02
EP3621635A4 (en) 2021-02-24
US20190194292A1 (en) 2019-06-27
KR20250118857A (ko) 2025-08-06
AU2018265258B2 (en) 2023-01-05
BR112018075281A2 (pt) 2020-02-11
IL263979B2 (en) 2023-09-01
IL263979A (en) 2019-02-28
RU2018146446A3 (cg-RX-API-DMAC10.html) 2021-09-10
KR20200005721A (ko) 2020-01-16
RU2018146446A (ru) 2021-06-10
IL263979B1 (en) 2023-05-01
KR20240073085A (ko) 2024-05-24
MX2018015599A (es) 2019-05-16
EP3621635A1 (en) 2020-03-18
KR102839445B1 (ko) 2025-07-28
US20220169701A1 (en) 2022-06-02
AU2018265258A1 (en) 2019-01-17
CN109414483B (zh) 2025-10-24
CA3026892A1 (en) 2018-11-15
KR102662049B1 (ko) 2024-05-23

Similar Documents

Publication Publication Date Title
US20220169701A1 (en) Enveloped Virus Resistant to Complement Inactivation for the Treatment of Cancer
JP2019512458A (ja) Ｒｎａによって誘導された、ヒトｊｃウイルス及び他のポリオーマウイルスの根絶
CA2172393A1 (en) Methods of stimulating phagocytosis
CN118973610A (zh) 通过中断细胞和病毒受体相互作用来阻断asfv感染的方法
KR20220125805A (ko) Cd70-양성 종양을 표적화하기 위해 천연 킬러 세포를 가공하는 방법
TW202122411A (zh) 以黏液瘤(myxoma)病毒治療癌症之新穎溶瘤病毒平臺
TW202600150A (zh) 編碼ccl21之重組棒狀病毒
WO2020055941A1 (en) Compositions and methods for excision with single grna
WO2023051701A1 (zh) 抗SARS-CoV-2感染的mRNA、蛋白以及抗SARS-CoV-2感染的疫苗
JP2023519083A (ja) 細胞がん治療の強化の為のｔ細胞死関連遺伝子８（ｔｄａｇ８）調節
CN114127301B (zh) 用于治疗肿瘤的药物组合物、药盒和方法
JP2025507939A (ja) がんワクチンおよびその使用方法
US12528853B2 (en) T-cell receptor for treating fibrolamellar hepatocellular carcinoma
JP2024508088A (ja) 全身送達及び抗腫瘍活性の向上のための腫瘍溶解性ウイルス
ES2946554A1 (es) Peptidos y composicion farmaceutica para el tratamiento de tumores
Singh et al. GENE THERAPY FOR ORAL CANCER-JOURNEY TO A NEW HORIZON.
Sun et al. Sickle cells produce functional immune modulators and cytotoxics
JP6640717B2 (ja) レトロウイルス複製ベクターと関連する免疫抑制成分
CN121319223B (zh) 一种靶向cd19和bcma的双特异性嵌合抗原受体及其相关产品和应用
CN115605586B (zh) 工程化溶瘤腺病毒
CN121406676A (zh) 用于免疫细胞衔接剂的核酸和药物组合物
JP2016160249A (ja) 腫瘍溶解改変アデノウイルス、疾患治療用改変ウイルス及びこれらを含むウイルス製剤
HK40104197A (en) Tnfsf-l fusion proteins and uses thereof
CN120173884A (zh) 功能优化的嵌合抗原受体效应细胞及其在制备治疗急性髓系白血病的组合物中的应用
CN121537531A (zh) 一种表达cd47-cd28共刺激转换受体的嵌合抗原受体及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210409

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210409

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220520

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220921

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221017

R150 Certificate of patent or registration of utility model

Ref document number: 7161940

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350